Trends in burden of multidrug-resistant tuberculosis in countries, regions, and worldwide from 1990 to 2017: results from the Global Burden of Disease Study

Zejin Ou
Southern Medical University

Danfeng Yu
Guangdong Maternal and Child Hospital

Yuanhao Liang
Southern Medical University

Wenqiao He
Southern Medical University

Yongzhi Li
Southern Medical University

Yaxian Meng
Southern Medical University

Husheng Xiong
Southern Medical University

Minyi Zhang
Southern Medical University

Huan He
Southern Medical University

Yuhan Gao
Southern Medical University

Fei Wu
Southern Medical University

Qing Chen (✉ qch.2009@163.com)
Southern Medical University

Research Article

Keywords: Multidrug-resistant tuberculosis, Global burden of disease, Age-standardized rate, Estimated annual percentage change, Epidemiological trend

DOI: https://doi.org/10.21203/rs.3.rs-63071/v2

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background Antituberculosis-drug resistance is an important public health issue worldwide, and its epidemiological patterns has dramatically changed in recent decades. This study aimed to estimate the trends of multidrug-resistant tuberculosis (MDR-TB), which can provide an important reference to the strategies for TB control.

Methods Data were collected from the Global Burden of Disease Study 2017. The estimated annual percentage changes (EAPCs) were calculated to quantify the trends of MDR-TB burden at global, regional, and national level from 1990 to 2017.

Results Globally, the age-standardized rate (ASR) of MDR-TB burden including incidence, prevalence, death and disability-adjusted life years (DALYs) had pronounced increasing trends from 1990 to 1999, with the respective EAPCs were 17.63 (95% confidence interval [CI]: 10.77 to 24.92), 17.57 (95%CI: 11.51 to 23.95), 21.21 (95%CI:15.96 to 26.69), and 21.90 (95%CI: 16.55 to 27.50). Particularly, the largest increasing trends were seen in areas and countries with low and low-middle sociodemographic index (SDI). However, the trends in incidence, prevalence, death and DALYs of MDR-TB decreased globally from 2000 to 2017, with the respective EAPCs were −1.37 (95%CI: −1.62 to −1.12), −1.32 (95%CI: −1.38 to −1.26), −3.30 (95%CI: −3.56 to −3.04) and −3.32 (95%CI: −3.59 to −3.06). Decreasing trends of MDR-TB were observed in most regions and countries, particularly that of death and DALYs in Slovenia were −18.96 (95%CI: −20.82 to −17.06) and −19.35 (95%CI: −21.10 to −17.55), respectively. Whereas increasing trends of MDR-TB occurred in Papua New Guinea, Singapore, and Australia.

Conclusions The trends of MDR-TB pronouncedly decreased worldwide from 2000 to 2017. However, the MDR-TB burden remains a substantial challenge to the TB control globally, and requires effective control strategies and healthcare systems.

Background

Resistance to anti-tuberculosis (TB) drugs has been an increasing challenge to global TB control in recent years[1, 2]. Multidrug-resistant tuberculosis (MDR-TB) is the major part of drug-resistant tuberculosis[3], and its trends are an important reference to the strategies of TB control.

MDR-TB is defined as the *Mycobacterium tuberculosis* that is resistant to isoniazid and rifampicin, which is strongly related to previous TB disease and its treatment[4, 5]. In the 1990s, MDR-TB outbreaks were reported in the USA and Europe[6, 7], and global surveillance of antituberculosis drug resistance was considered urgent and necessary. In 1994, a global program on surveillance of drug-resistant tuberculosis was launched by the World Health Organization (WHO), and the results showed that MDR-TB had increased dramatically worldwide[8, 9]. During 1994 and 1997, the global prevalence of MDR-TB was 1.4% in new TB patients, and 13% for TB patients treated previously[10]. It was reported that global MDR-TB occurred in an estimated 460,000 cases and resulted in 230,000 deaths in 2017, and accounted for 3.6% of all new cases and 17% of treated cases[11]. The highest burden of MDR-TB has been reported to be in China, India, Russia, and South Africa, and those countries have >60% of all cases worldwide[12]. Meanwhile, the increasing MDR-TB has elicited problems with decreasing cure rates and survival times[13]. Furthermore, the MDR-TB prevalence has soaked up 47% of the expense for the response to anti-TB programs globally[14], and strained local health resources[8, 15]. These alarming data showed the urgent need for MDR-TB control.

The WHO set a “End TB” strategy based on a 90% decrease in the TB incidence documented in 2015 to be reached by 2035[16]. More efficient strategies and increasing investment and commitment to MDR-TB control will be needed[17], which emphasized the necessity to track the epidemiological trends of the MDR-TB burden. The Global Burden of
Disease (GBD) study had provided a methodological and conceptual framework to quantify health loss, which facilitates the assessment of progress and challenges in the MDR-TB control. Here, we estimated trends in the MDR-TB burden from 1990 to 2017 using data derived from the GBD 2017, which would facilitate the improvement of strategies for TB control.

**Materials And Methods**

**Data source**

The data of MDR-TB were acquired from Global Burden of Disease (GBD) study with the Global Health Data Exchange query tool (http://ghdx.healthdata.org/gbd-results-tool). According to the GBD online tools instruction, the number and rate of MDR-TB incidence, prevalence, death, and disability-adjusted life years (DALYs) were extracted based on age, sex, sociodemographic index (SDI) area, geographic region, and country, without any inclusion/exclusion criteria. Age was stratified into five groups: < 5, 5-14, 15-49, 50-69, and > 70 years. The SDI areas were categorized five levels: "low", "low-middle", "middle", "high-middle", and "high". According to geographic factor, the world was divided into 21 geographic regions, and 195 countries/territories. The Human Development Index (HDI) reflects the level of human development, and the availability of health resources in regions and countries. The data of HDI at national level were obtained from the United Nations Development Program (http://hdr.undp.org/en/data).

**Statistical analyses**

The age-standardized rate (ASR) is a critical and representative parameter when considering differences in the age structure of multiple populations. The ASR is a weighted mean of age-specific rates. The ASR is calculated on basis of the age structure of standard populations using the following formula:

\[
\text{ASR} = \frac{\sum_i a_i w_i}{\sum_i w_i} \times 100,000
\]

where \(a_i\) is the age-specific rate in the \(i^{th}\) age group, \(w_i\) is the number of persons (or the weight) in the corresponding \(i^{th}\) age subgroup of the selected reference standard population, and \(A\) is the number of age groups.

The ASR trend is a widely accepted measure that estimates the changing patterns of disease burden. The estimated annual percentage change (EAPC) is a common index reflecting the temporal trend of ASR, which has been described in detail elsewhere[18]. A regression line was fitted to the natural logarithm of the ASR. EAPC and its 95% confidence interval (CI) were estimated by using the linear regression model. The formula is as following: 

\[
y = \alpha + \beta x + \epsilon
\]

EAPC=100×(exp(β)−1)

where \(y=\ln\text{ (ASR)}\), and \(x\) is the calendar year. The trends were judged: if the EAPC and its 95%CI were >0, the ASR was in an increasing trend; if EAPC and its 95%CI were <0, the ASR was in a decreasing trend; other values meant that the ASR was stable over time. The Pearson correlation analysis was used to detect the factors influencing the EAPC at the national level, including the ASR and HDI. Data were analyzed using SPSS v20.0 (IBM, Armonk, NY, USA). The choropleth maps were drawn using R v3.6.2 (R Project for Statistical Computing, Austria, Vienna).

**Results**

**Trends in MDR-TB incidence**
During the period 1990-1999, the incidence of MDR-TB had a pronounced rising trend globally, with the overall age-standardized incidence rate (ASIR) increasing by an annual average of 17.63% (EAPC=17.63, 95%CI: 10.77 to 24.92). The upward trends of ASIR occurred in all SDI areas and geographic regions, except high-income North America (Table 1; Figure 1A). At the national level, the ASIR of MDR-TB showed increasing trends in 186 countries/territories, particularly Turkmenistan, Somalia, and Kyrgyzstan, with the EAPCs were 66.78 (95%CI: 55.5 to 78.89), 66.08 (95%CI: 55.93 to 76.89), and 63.94 (95%CI: 51.99 to 76.84), respectively. However, the downward trends of ASIR were observed only in United States (EAPC=−6.78, 95%CI: −8.19 to −5.36) (Supplementary table 4; Supplementary figure 7A-C).
Table 1
the percentage changes in absolute number and EAPCs of MDR-TB incidence from 1990 to 2017 in global, sexes, SDI areas and geographic regions

| Characteristics | 1999 | 1990–1999 | 2017 | 2000–2017 |
|-----------------|------|-----------|------|-----------|
|                 | Number $\times 10^3$ (95% UI) | ASR per 100 k No. (95% UI) | Percentage Change in absolute number (%) | EAPCs (95%CI) | Number $\times 10^3$ (95% UI) | ASR per 100 k No. (95% UI) | Percentage Change in absolute number (%) | EAPCs (95%CI) |
| Overall         | 383.50 | 6.41 | 558.06 | 17.63 | 432.77 | 5.55 | 8.29 | −1.37 |
|                 | (290.12–517.25) | (4.85–8.64) | (10.77–24.92) | (254.61–726.95) | (3.29–9.29) | (−1.62–−1.12) |
| Sex             |       |       |       |       |       |       |       |       |
| Male            | 215.27 | 7.36 | 575.03 | 17.89 | 240.92 | 6.17 | 7.13 | −1.58 |
|                 | (165.10–285.45) | (5.63–9.77) | (11.09–25.1) | (145.81–396.46) | (3.75–10.14) | (−1.81–−1.34) |
| Female          | 168.23 | 5.55 | 537.55 | 17.30 | 191.85 | 4.99 | 9.80 | −1.13 |
|                 | (124.10–232.42) | (4.10–7.66) | (10.36–24.67) | (109.57–334.02) | (2.86–8.66) | (−1.4–−0.86) |
| SDI             |       |       |       |       |       |       |       |       |
| Low             | 57.85 | 8.17 | 2054.73 | 32.73 | 121.88 | 11.23 | 90.22 | 1.08 |
|                 | (31.12–110.89) | (4.30–16.14) | (24.72–41.25) | (60.13–247.13) | (5.28–23.28) | (0.85–1.3) |
| Low-middle      | 82.58 | 7.59 | 1243.54 | 26.40 | 145.89 | 9.32 | 61.69 | 0.47 |
|                 | (47.27–145.63) | (4.25–13.67) | (18.82–34.46) | (70.89–263.95) | (4.44–17.28) | (0.11–0.84) |
| Middle          | 135.47 | 8.14 | 366.99 | 13.27 | 96.80 | 4.44 | −28.73 | −3.9 |
|                 | (87.38–194.95) | (5.26–11.8) | (6.4–20.59) | (48.14–175.83) | (2.22–8.1) | (−4.17–−3.63) |
| High-middle     | 98.64 | 7.90 | 463.10 | 15.79 | 64.68 | 4.12 | −35.78 | −4.08 |
|                 | (66.20–143.87) | (5.26–11.56) | (8.51–23.55) | (42.19–96.12) | (2.70–6.14) | (−4.63–−3.54) |
| High            | 6.05 | 0.54 | 183.49 | 9.29 | 2.86 | 0.22 | −52.36 | −6.25 |
|                 | (3.90–10.40) | (0.34–0.94) | (4.32–14.50) | (1.75–5.15) | (0.14–0.38) | (−6.93–−5.57) |

MDR-TB: multidrug resistant tuberculosis; EAPC: estimated annual percentage change; ASR, age-standardized rate; CI, confidence interval; UI: uncertainty interval; SDI: socio-demographic index.
| Regions                  | 1999      | 1990–1999 | 2017      | 2000–2017 |
|--------------------------|-----------|-----------|-----------|-----------|
| East Asia                | 174.58    | 13.08     | 272.72    | 11.31     | 35.78     | 2.22     | -78.58   | -10.98   |
|                          | (118.01–246.69) | (8.89–18.48) | (4.02–19.11) | (8.19–111.13) | (0.51–6.96) | (-11.66–10.29) |
| South Asia               | 88.80     | 7.82      | 4328.87   | 42.85     | 216.16    | 12.96    | 112.02   | 1.91     |
|                          | (32.12–200.49) | (2.84–17.74) | (32.57–53.93) | (59.52–491.95) | (3.54–29.61) | (1.34–2.49) |
| Southeast Asia           | 18.74     | 4.01      | 891.37    | 21.07     | 20.14     | 3.11     | 4.47     | -1.36    |
|                          | (9.13–47.79) | (1.98–10.04) | (11.74–31.17) | (11.97–32.22) | (1.85–4.94) | (-1.6–-1.13) |
| Central Asia             | 5.85      | 8.23      | 6722.47   | 48.26     | 15.00     | 16.14    | 112.47   | 1.87     |
|                          | (3.87–9.25) | (5.42–12.93) | (33.64–64.48) | (11.24–19.68) | (12.07–21.23) | (-0.35–4.14) |
| High-income Asia Pacific | 1.54      | 0.71      | 254.03    | 10.85     | 0.77      | 0.29     | -50.42   | -7.3     |
|                          | (1.13–2.20) | (0.51–1.03) | (5.12–16.88) | (0.18–2.12) | (0.07–0.82) | (-8.7–-5.87) |
| Oceania                  | 0.06      | 0.88      | 1528.54   | 28.75     | 0.57      | 4.80     | 710.75   | 9.53     |
|                          | (0.01–0.20) | (0.18–0.27) | (21.89–36) | (0.29–1.00) | (2.44–8.35) | (7.93–11.15) |
| Australasia              | 0.01      | 0.05      | 61.42     | 3.86      | 0.04      | 0.15     | 323.96   | 7.54     |
|                          | (0.005–0.02) | (0.02–0.10) | (1.31–6.47) | (0.03–0.07) | (0.09–0.24) | (7.09–8) |
| Eastern Europe           | 30.93     | 12.70     | 1667.60   | 31.15     | 41.35     | 17.64    | 21.56    | 1.41     |
|                          | (22.15–42.10) | (9.12–17.28) | (21.59–41.46) | (27.21–57.89) | (11.54–24.59) | (0.16–2.66) |
| Western Europe           | 0.70      | 0.18      | 144.69    | 9.58      | 0.73      | 0.18     | 0.56     | -1.01    |
|                          | (0.59–0.81) | (0.15–0.21) | (8.21–10.97) | (0.57–0.95) | (0.14–0.23) | (-1.51–-0.51) |
| Central Europe           | 0.79      | 0.60      | 354.42    | 14.17     | 0.58      | 0.45     | -27.56   | -2.29    |
|                          | (0.53–1.30) | (0.39–0.97) | (6.6–22.27) | (0.39–0.82) | (0.29–0.63) | (-3.28–-1.29) |

MDR-TB: multidrug resistant tuberculosis; EAPC: estimated annual percentage change; ASR, age-standardized rate; CI, confidence interval; UI: uncertainty interval; SDI: socio-demographic index.
| Region                      | 1999  | 1990–1999 | 2017  | 2000–2017 |
|-----------------------------|-------|-----------|-------|-----------|
| High-income North America   | 0.23  | 0.07      | -38.50| -41.23    |
|                            | (0.19–| 0.05–     | (-7.68–| (-3.33–   |
|                            | 0.28) | 0.08)     | -4.86) | -2.59)    |
| Andean Latin America        | 3.23  | 7.64      | 773.25| -18.48    |
|                            | (1.59–| 3.76–     | (18.12–| (-4.41–   |
|                            | 5.84) | 13.79)    | 26.83) | -3.54)    |
| Central Latin America       | 1.02  | 0.62      | 2211.58| 28.99     |
|                            | (0.59–| 0.35–     | (20.52–| (-2.35–   |
|                            | 1.81) | 1.08)     | 42.54) | -1.16)    |
| Caribbean                   | 0.17  | 0.44      | 167.35| -44.12    |
|                            | (0.07–| 0.17–     | (4.22–| (-7.83–   |
|                            | 0.48) | 1.22)     | 12.98) | -3.71)    |
| Tropical Latin America      | 1.40  | 0.84      | 5272.18| 37.90     |
|                            | (0.38–| 0.23–     | (39.68–| (-1.42–   |
|                            | 3.57) | 2.11)     | 57.64) | 0.41)     |
| Southern Latin America      | 0.17  | 0.32      | 511.06| -40.47    |
|                            | (0.10–| 0.18–     | (16.21–| (-6.87–   |
|                            | 0.30) | 0.54)     | 22.79) | -4.79)    |
| Eastern Sub-Saharan Africa  | 17.55 | 8.75      | 3920.28| 78.79     |
|                            | (10.87–| 5.23–     | (29.48–| (-0.17–   |
|                            | 28.72) | 14.98)    | 51.53) | 0.35)     |
| Southern Sub-Saharan Africa | 8.03  | 12.38     | 707.05| 20.43     |
|                            | (4.20–| 6.47–     | (22.54–| (-0.46–   |
|                            | 17.60) | 27.75)    | 23.67) | 0.96)     |
| Western Sub-Saharan Africa  | 17.21 | 8.32      | 1164.55| 62.28     |
|                            | (7.77–| 3.76–     | (17.01–| (-0.48–   |
|                            | 38.43) | 18.33)    | 32.47) | -0.06)    |
| North Africa and Middle East| 6.76  | 1.74      | 1760.45| -2.56     |
|                            | (4.11–| 1.06–     | (28.65–| (-2.73–   |
|                            | 10.36) | 2.67)     | 38.46) | -2.39)    |

MDR-TB: multidrug resistant tuberculosis; EAPC: estimated annual percentage change; ASR, age-standardized rate; CI, confidence interval; UI: uncertainty interval; SDI: socio-demographic index.
|                | 1999     | 1990–1999 | 2017     | 2000–2017 |
|----------------|----------|-----------|----------|-----------|
| Central Sub-Saharan Africa | 5.72     | 10.17     | 673.46   | 18.11     |
|                |          |           |          |           |
|                | (1.73–16.90) | (3.12–29.55) | (10.74–25.97) | (2.97–34.12) |
|                |          |           |          |           |
|                | 12.01    | 12.33     | 99.63    | 0.65      |
|                | (2.87–32.58) | (2.97–34.12) | (0.45–0.85) |           |

MDR-TB: multidrug resistant tuberculosis; EAPC: estimated annual percentage change; ASR, age-standardized rate; CI, confidence interval; UI: uncertainty interval; SDI: socio-demographic index.

Globally, the incident number of MDR-TB was $432.70 \times 10^3$ (95% uncertainty interval (UI): $254.61 \times 10^3$ to $726.95 \times 10^3$) in 2017, with a decrease of 8.29% since 2000. From 2000 to 2017, the ASIR had a decreasing trend (EAPC=−1.37, 95%CI: −1.62 to −1.12) (Table 1; Figure 1B). The decreasing trends of ASIR were seen in SDI areas, expect low and low-middle SDI areas. In terms of 21 regions, the most pronounced decreasing trends were seen in East Asia and High-income Asia Pacific, in which EPACs were −10.98(95%CI: −11.66 to −10.29) and −7.30(95%CI: −8.70 to −5.87). Whereas the largest increasing trends occurred in Oceania (EAPC=9.53, 95%CI:7.93 to 11.15) (Table 1; Figure 1B, and Figure 2A-C). Among 195 countries/territories, the ASIR showed downward trends in 112 countries, and the largest one was in Slovenia from 2000 to 2017 (EAPC=−14.11, 95%CI: −15.36 to −12.83). While the ASIR showed increasing trends in 54 countries, particularly Papua New Guinea (EAPC=9.83, 95%CI: 8.23 to 11.45), followed by Australia and Finland. (Supplementary table 5; Figure 3A-C). The EAPCs (2000-2017) had a positive correlation with the ASIR in 2000 at a national level ($\rho$=0.25, p<0.001) (Figure 4A), but no with the HDI in 2017.

**Trends in MDR-TB prevalence**

Globally, the ASR of prevalence showed an obvious upward trend from 1990 to 1999, with the EAPC was 17.57 (95%CI: 11.51 to 23.95). Meanwhile, the similar trends were also observed in SDI areas and geographic regions (Supplementary table 1; Figure 1A). With regard to national level, during the period 1990-1999, the rising trends of prevalence were observed in 185 countries/territories, and the largest one was in Somalia (EAPC=67.92, 95%CI: 58.28 to 78.16), followed by Turkmenistan, and Kyrgyzstan. However, the trends decreased only in United States, with the EAPC of −10.84(95%CI: −11.4 to −10.28) (Supplementary table 4; Supplementary figure 8A-C).

The number of MDR-TB prevalence was $464.12 \times 10^3$ (95%UI: $229.12 \times 10^3$ to $863.33 \times 10^3$) worldwide in 2017, with an increase of 9.92% since 2000. During the period 2000-2017, the prevalence of MDR-TB had a decreasing trend, with the EAPC was −1.32 (95%CI: −1.38 to −1.26) (Supplementary table 1; Figure 1). The trends decreased in SDI areas, expect low- and low-middle ones. Among 21 geographical regions, the most pronounced downward trends were observed in High-income Asia Pacific (EAPC= −8.77, 95%CI: −9.98 to −7.55), while the largest increasing trends occurred in Oceania and Australasia (Supplementary table 1; Figure 1B, and Supplementary figure 1A-C). Decreasing trends of prevalence were observed in 104 countries, particularly Slovenia (EAPC=−13.69, 95%CI: −15.04 to −12.31). While the increasing trends occurred in 55 countries, and the largest one was in Papua New Guinea (EAPC=9.28, 95%CI: 7.81 to 10.78), followed by Finland and Australia (Supplementary table 5; Supplementary figure 4A-C). The EAPCs (2000-2017) had a positive correlation with the ASR of prevalence in 2000 at a national level (p=0.18, p=0.02) (Figure 4B), but no with the HDI in 2017.
Trends in death caused by MDR-TB

Globally, the age-standardized death rate (ASDR) of MDR-TB had a rising trend from 1990 to 1999 (EAPC=21.21, 95%CI: 15.96 to 26.69). During the period 1990-1999, the upward trends of ASDR were observed in all SDI areas and most geographic regions, whereas the decreasing trend occurred only in high-income North America (EAPC=−15.91, 95%CI: −18.52 to −13.22) (Supplementary table 2; Figure 1A). Among 195 countries/territories, increasing trends were documented in 186 countries/territories, and the largest increasing occurred in Somalia (EAPC=81.08, 95%CI:72.54 to 90.05), followed by Kyrgyzstan, and Turkmenistan. However, the decreasing trends were seen in seven countries, particularly United States (EAPC=−16.72, 95%CI: −19.41 to −13.94) (Supplementary table 4; Supplementary figure 9A-C).

The number of deaths caused by MDR-TB was 126.89×10^3 (95%UI: 70.06×10^3 to202.17×10^3) worldwide in 2017, with a decrease of 10.17% since 2000. The ASDR of MDR-TB had a decreasing trend from 2000 to 2017 (EAPC=−3.30, 95%CI: −3.56 to −3.04) (Supplementary table 2; Figure 1B). The ASDR had downward trends in all SDI areas and geographic regions, particularly East Asia (EAPC=−13.57, 95%CI: −14.95 to −12.16), followed by High-income Asia Pacific and Southern Latin America (Supplementary table 2; Figure 1B, and Supplementary figure 2A-C). From 2000 to 2017, increasing trends of ASDR were observed in seventeen countries, particularly Singapore (EAPC=12.67, 95%CI: 10.6 to 14.78). On the other hand, the decreasing trends were demonstrated in 164 countries/territories, and the largest one was in Slovenia (EAPC=−18.96, 95%CI: −20.82 to −17.06), followed by Maldives, and Laos (Supplementary table 5; Supplementary figure 5A-C). The EAPCs (2000-2017) had a positive correlation with the ASDR in 2000, and a negative one with the HDI in 2017 at a national level (p=0.27, p<0.001, Figure 4C; p=−0.18, p=0.017, Figure 5A, respectively).

Trends in DALYs caused by MDR-TB

Pronounced increasing trend was observed in DALYs caused by MDR-TB from 1990 to 1999, with an EAPC was 21.90(95%CI: 16.55 to 27.50). Increasing trends were also seen in all SDI areas and geographic regions, and the largest ones were in Central Asia (EAPC=62.87, 95%CI:47.83 to 79.44), followed by Tropical Latin America, and South Asia (Supplementary table 3; Figure 1A). Rising trends of DALYs were observed in 163 countries/territories, with the most pronounced ones being in Somalia (EAPC=−13.96, 95%CI: −20.82 to −17.06), followed by Maldives, and Laos (Supplementary table 5; Supplementary figure 5A-C). The EAPCs (2000-2017) had a positive correlation with the ASR of DALYs in 2000, and a negative one with the HDI in 2017 at a national level (p=0.27, p<0.001, Figure 4D; p=−0.18, p=0.017, Figure 5A, respectively).

Globally, the number of DALYs caused by MDR-TB was 4647.99×10^3 (95%UI: 2663.04×10^3 to7224.23×10^3) in 2017, with an increase of −17.71% since 2000. The ASR of DALYs had a decreasing trend from 2000 to 2017 (EAPC=−3.32, 95%CI: −3.59 to −3.06) (Supplementary table 3; Figure 1B). The downward trends of DALYs were observed in SDI areas and regions, expect Oceania and Australasia. The largest decreasing trends of DALYs were seen in East Asia and High-income Asia Pacific, in which the EAPCs were −13.02(95%CI: −13.58 to −12.46) and −12.62(95%CI: −13.85 to −11.38), respectively (Supplementary table 2; Figure 1B, and Supplementary figure 3A-C). Increasing trends were observed in nineteen countries/territories, with the largest one being in Singapore (EAPC=9.28, 95%CI: 7.78 to 10.79), followed by Papua New Guinea and Zimbabwe. On the other hand, the decreasing trends were observed in 164 countries/territories, particularly Slovenia, Maldives, and Laos, in which the EAPCs were −19.35(95%CI: −21.1 to −17.55), −17.50(95%CI: −18.33 to −16.66), and −14.63(95%CI: −15.65 to −13.59), respectively (Supplementary table 5; Supplementary figure 6A-C). The EAPCs (2000-2017) had a positive correlation with the ASR of DALYs in 2000, and a negative one with the HDI in 2017 at a national level (p=0.26, p<0.001, Figure 4D; p=−0.16, p=0.029, Figure 5B, respectively).
Discussion

In present study, we observed that the data presented a parabolic distribution, and 1999 was selected as the time cut-off point to describe its trends in two time intervals, including 1990-1999, and 2000-2017. The ASR of MDR-TB including incidence, prevalence, death, and DALYs, dramatically increased globally between 1990 and 1999, but showed decreasing trends from 2000 to 2017.

During the period 1990-1999, the number of MDR-TB rapidly rose globally, and the ASR had the largest increasing trends in the areas of low and low-middle SDI areas. In these areas, there existed many stumbling blocks to TB control, including population expansion, poverty, and overloaded health systems[19, 20]. These factors could also explain why the EAPCs were negatively associated with HDI in this article. Among geographic regions, central Asia showed the largest increasing trends of MDR-TB. TB patients living in former Soviet countries had a high risk of MDR-TB development[21], probably attributed to a transmissible branch of the *M. tuberculosis* Beijing genotype: central Asia outbreak clade[22]. Somalia, Turkmenistan, and Kyrgyzstan had the most pronounced increasing trends of MDR-TB from 1990 to 1999. In these countries, poverty, malnutrition and poor health infrastructure are considerable contributors to the development of MDR-TB [23, 24]. Furthermore, the situation has been accelerated by an inundation of drug use and human immunodeficiency virus (HIV) infection[25, 26]. Whereas a decreasing trend of MDR-TB was observed in high-income North America, where the robust healthcare systems could treat TB effectively, and consequently to reduce the development of MDR-TB[27].

However, the decreasing trends of MDR-TB occurred worldwide, in most regions, and countries from 2000 to 2017, which was probably due to the effective management and control of TB in recent years. The global tuberculosis report 2018 revealed that TB incidence was falling at about 2% per year, and the overall reduction of mortality rate during 2000-2017 was estimated to be 42%[28]. The testing, detection and treatment of MDR-TB had achieved apparent progress globally, for example, up to 41% of TB patients were tested for rifampicin resistance in 2017[29], and recommendations on the treatment and care of drug-resistant tuberculosis has been compiled and issued by World Health Organization (WHO) from 2011 to 2019[30]. Meanwhile, management of MDR-TB contacts had been developed in recent years, and the preventive therapy (TPT) could reduce the risk to development of MDR-TB by up to 90%[31]. Particularly, governments and political organizations have taken action for DR-TB control through action plans, financial initiatives, and health infrastructure worldwide[32, 33]. For example, a national survey in 2007 revealed a serious drug-resistant tuberculosis epidemic appeared in China, and estimated that 10% of TB patients had MDR-TB[34]. The Chinese government started to revitalize anti-TB programs in 1990s, and carried out forceful measures to achieve considerable successes in MDR-TB control[35]. A meta-analysis confirmed that the prevalence of MDR-TB had a decreasing trend in China from 1996 to 2014[36]. Simultaneously, the government carried out national initiatives, including reducing poverty, improving health infrastructure, and implementing a new medical-care system in rural areas.[37] Surprisingly, several countries with a low incidence of tuberculosis exhibited obvious increasing trends of MDR-TB from 2000 to 2017, including Singapore, Australia and Papua New Guinea. These countries hold the most frequent population migration all over the world. In Singapore, 80% of MDR-TB patients occurred among the foreign population during 2000-2010, with an increasing trend after 2004[38]. Papua New Guinea has a high TB burden, and causes challenges to cross-border management of MDR-TB in the Torres Strait, Australia[39]. Therefore, the importance of pre-immigration screening to detect the infectious disease should be emphasized[40].

Our study had three main limitations. First, estimation of disease burden was dependent mainly on the quality and quantity of data, and the accuracy and robustness of GBD estimates may be impaired by a potential bias, including unreported cases, incomplete testing and reporting, and the test technology of MDR-TB varied across countries and
over time. Second, because of the limitation of ASR estimates, the trends of MDR-TB in age groups only were presented using percentage changes in absolute numbers. Third, the risk factors and clinical information of MDR-TB were not available, so the reason for the changing trends could not be investigated further.

**Conclusion**

The trends of MDR-TB burden dramatically increased worldwide during the 1990-1999, whereas decreasing trends were observed worldwide, and in most regions and countries from 2000 to 2017. However, the MDR-TB burden remains a substantial challenge to the public health globally, and more efficient strategies and increasing investment to the prevention and control of MDR-TB are required.

**List Of Abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| DALYs        | disability-adjusted life-years |
| GBD          | global burden of disease |
| SDGs         | sustainable development goals |
| EAPC         | estimated annual percentage change |
| ASR          | age-standardized rate |
| CI           | confidence interval |
| UI           | uncertainty interval |
| SDI          | socio-demographic index |
| HDI          | human development index |
| MDR-TB       | multidrug-resistant tuberculosis |
| TPT          | the preventive therapy |

**Declarations**

**Ethical approval and consent to participate:** Not applicable.

**Consent for publication:** All authors consent for publication of the manuscript.

**Availability of supporting data:** All data during this study are included in this published article and its supplementary information files.

**Competing interests:** The authors declare no competing interests.

**Funding:** no funding was disclosed.

**Authors’ contributions:**

Zejin Ou: Project administration and drafting.

Danfeng Yu, Yaxian Meng, Yuhan Gao: Data analysis and validation.
Yuanhao Liang, Husheng Xiong: Data analysis and visualization.
Wenqiao He, Yongzhi Li, Minyi Zhang, Fei Wu, Huan He: Data collection and collation. QC: supervision and drafting and editing.

**Acknowledgment:** Not applicable.

**Authors’ information:**

Zejin Ou, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: ouzejin@163.com

Danfeng Yu, Department of MICU, Guangdong Women and Children Hospital, Guangzhou, China. Email: yudanfeng007@126.com

Yuanhao Liang, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: lyhlytlyh@gmail.com

Wenqiao He, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 1457650753@qq.com

Yongzhi Li, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 530687791@qq.com

Yaxian Meng, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 13111218995@163.com

Husheng Xiong, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 357750569@qq.com

Minyi Zhang, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 505133884@qq.com

Huan He, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 352452705@qq.com

Yuhan Gao, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 1820106535@qq.com

Fei Wu, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China. Email: 961941783@qq.com

Qing Chen, Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University, 1838 Guangzhou North Road, Guangzhou, 510515, China. Tel: +86-020-61648312. Email: qch.2009@163.com.

**References**

1. Nathanson E NP, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, Weil D, Raviglione M. MDR tuberculosis–critical steps for prevention and control. N Engl J Med. 2010;363(11):1050-8.
2. Mariandyshev A EP. Drug-resistant tuberculosis threatens WHO’s End-TB strategy. Lancet Infect Dis. 2017;17(7):674-5.

3. Sharma SK MA. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest. 2006;130(1):261-72.

4. Pradipita IS FL, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018;77(6):469-78.

5. van der Werf MJ LM, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J. 2012;39(6):1511-9.

6. Frieden TR ST, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328(8):521-6.

7. Monno L AG, Carbonara S, Coppola S, Costa D, Quarto M, Pastore G. Emergence of drug-resistant Mycobacterium tuberculosis in HIV-infected patients. Lancet. 1991;337(8745):852.

8. Dheda K GT, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udewadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlrion K, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(17):291-360.

9. Falzon D DJ. World TB day: European countries report over 400,000 tuberculosis cases in 2004. Euro Surveill. 2006;11(3):E060323 3.

10. Pablos-Mendez A RM, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998;338(23):1641-9.

11. WHO. Global tuberculosis report Geneva, Switzerland: World Health Organization, 2018.

12. Zignol M vGW, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012;90(2):111-9D.

13. Shah NS PR, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA. 2008;300(18):2153-60.

14. WHO. Global tuberculosis report 2014. Switzerland: World Health Organization, 2014.

15. O'Donnell MR JJ, Loveday M, Padayatchi N, Zelnick J, Werner L, Naidoo K, Master I, Osburn G, Kvasnovsky C, Shean K, Pai M, Van der Walt M, Horsburgh CR, Dheda K. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010;153(8):516-22.

16. WHO. The WHO End TB Strategy. Geneva, Switzerland: World Health Organization, 2015.

17. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet. 2019;393(10178):1331-84.

18. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70(4):674-83.
19. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet. 2010;375(9732):2179-91.

20. Zhao P LX, Zhang SF, Wang XS, Liu CY. Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res. 2012;40(2):436-45.

21. Falzon D IA, Ait-Belghiti F. In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. International Journal of Tuberculosis and Lung Disease. 2006;10(9):954-8.

22. Shitikov E VA, Malakhova M, Guliaev A, Bespyatyk J, Proshina E, Pasechnik O, Mokrousov I. Simple Assay for Detection of the Central Asia Outbreak Clade of the Mycobacterium tuberculosis Beijing Genotype. J Clin Microbiol. 2019;57(7):215-9.

23. S M. Preventing nosocomial MDR TB transmission in sub Saharan Africa: where are we at? Glob J Health Sci. 2013;5(4):200-10.

24. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009;373(9678):1861-73.

25. Schluge N, El-Bassel N, Hermosilla S, Terlikbayeva A, Darisheva M, Aifah A, Galea S. Tuberculosis, drug use and HIV infection in Central Asia: an urgent need for attention. Drug Alcohol Depend. 2013;132 Suppl 1:S32-6.

26. Harries AD HN, Kemp J, Jindani A, Enarson DA, Maher D, Salaniponi FM. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 2001;357(9267):1519-23.

27. Prevention CfDCa. Trends in tuberculosis - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(11):181-5.

28. WHO. Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization, 2018.

29. WHO. Process overview: development of a global strategy for TB research and innovation Geneva: World Health Organization, 2019.

30. WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2020.

31. Marks SM MS, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2017;64(12):1670-7.

32. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529-39.

33. Raviglione M MB, Floyd K, Lonroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet. 2012;379(9829):1902-13.

34. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161-70.

35. Bhatte R CA, Mistry N. The dragon and the tiger: realities in the control of tuberculosis. Interdiscip Perspect Infect Dis. 2012;2012:625459.

36. Zhang J GH, Hu X, Hu X, Shang M, Zhou J, Zhou Y, Ye Y, Song X, Lu X, Chen X, Ying B, Wang L. Status of drug-resistant tuberculosis in China: A systematic review and meta-analysis. Am J Infect Control. 2016;44(6):671-6.

37. Zhang D SL, Tian F, Zhang L. Care Utilization with China's New Rural Cooperative Medical Scheme: Updated Evidence from the China Health and Retirement Longitudinal Study 2011-2012. Int J Behav Med. 2016;23(6):655-
63.

38. Chee CB K-MK, Cutter J, Wang YT. The imminent threat of multidrug-resistant tuberculosis in Singapore. Singapore Med J. 2012;53(4):238-40.

39. Francis JR MP, Blyth CC, Denholm J, Lowbridge C, Coulter C, Donnan E, Stapledon R, Krause VL, Waring J. Multidrug-resistant tuberculosis in Australia, 1998-2012. Int J Tuberc Lung Dis. 2018;22(3):294-9.

40. Lowenthal P WJ, Moore M, Posey DL, Watt JP, Flood J. Reduced importation of tuberculosis after the implementation of an enhanced pre-immigration screening protocol. Int J Tuberc Lung Dis. 2011;15(6):761-6.